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Abstract.
Background: Behavioral and psychological symptoms of dementia (BPSD) are a group of psychological reactions, psychiatric
symptoms, and behaviors commonly found in Alzheimer’s disease (AD). Four clusters of BPSD have been described: mood
disorders (depression, anxiety, and apathy), psychotic symptoms (delusions and hallucinations), aberrant motor behaviors
(pacing, wandering, and other purposeless behaviors), and inappropriate behaviors (agitation, disinhibition, and euphoria).
Most of them are attributed to acetylcholine deficiency.
Objective: To evaluate if a higher amount of acetylcholine obtained by associating donepezil and choline alphoscerate might
have a favorable effect on BPSD.
Methods: BPSD were measured at baseline and after 24 months in 113 mild/moderate AD patients, included in the double-
blind randomized trial ASCOMALVA, by the Neuropsychiatric Inventory (NPI). Two matched groups were compared:
group A treated with donepezil (10 mg/day) plus choline alphoscerate (1200 mg/day), and group B treated with donepezil
(10 mg/day) plus placebo.
Results: Data of NPI revealed a significant decrease of BPSD severity and distress of the caregiver in patients of group A
compared with group B. Mood disorders (depression, anxiety and apathy) were significantly decreased in subjects treated
with donepezil and choline alphoscerate, while their severity and frequency was increased in the other group.
Conclusions: Patients treated with donepezil plus choline alphoscerate showed a lower level of behavioral disturbances than
subjects treated with donepezil only, suggesting that the association can have beneficial effects.
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INTRODUCTION
Behavioral and psychological symptoms of
dementia (BPSD) are a group of psychological reac-
tions, psychiatric symptoms, and behaviors often
ISSN 1387-2877/17/$35.00 © 2017 – IOS Press and the authors. All rights reserved
806 A. Carotenuto et al. / Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer’s Disease
occurring in dementia patients [1, 2]. BPSD preva-
lence is of about 30% in the subjects living in
the general community [3, 4] and rises to 80% in
those living in nursing facilities [5]. Up to 90% of
Alzheimer’s disease (AD) patients have at least one
BPSD [6].
The impact of BPSD on direct and indirect costs of
AD [7] leads to higher institutionalization rate [8, 9].
BPSD impair the quality of life of the caregivers [10],
contributing to AD intangible costs, an aspect which
is still overlooked, but which deserves attention and
should thus be accurately evaluated [7]. On the other
hand, BPSD raise ethical questions about care, auton-
omy, safety, and treatment. For instance, a reasonable
question is what interventions and treatments could
be recommended for dementia-related behaviors and
if anti-psychotic medications are an acceptable ther-
apy for the treatment of dementia-related behavioral
disturbances. This due to the reported increased risk
of mortality associated with antipsychotics in patients
with BPSD [8–10]. Several other ethical concerns
come from the use of electronic tracking for AD
individuals at risk for wandering [11].
Four clusters of BPSD have been described:
mood disorders (depression, anxiety, and apa-
thy/indifference), psychotic symptoms (delusions
and hallucinations), aberrant motor behaviors (pac-
ing, wandering, and other purposeless behaviors),
and inappropriate behaviors (agitation, disinhibition,
and euphoria), the last two more associated to faster
cognitive and functional decline [12]. Genetic fac-
tors are related to each cluster [13, 14]. BPSD causes
are still unclear. Besides the contribution of psycho-
logical and social aspects, including the premorbid
personality, the environmental modifications, and the
caregiving style, alterations of several neurotrans-
mitters (GABA, serotonin, noradrenaline) and of
the related pathways are certainly involved. Among
them, the main role is attributed to acetylcholine
reduction and consequent dysfunctions of the brain
cholinergic system [15].
The treatment of BPSD [16] is essentially
based on antipsychotics, antidepressants, and ben-
zodiazepines. Antipsychotics can ameliorate the
symptoms in the short term [17], but older subjects
are very sensitive to their undesirable effects that may
lead to a further functional decline and the risk of
pharmacological interactions [18]. The safety profile
of these compounds is also questionable in elderly
people, having been reported that these compounds
may increase the risk of cerebrovascular events
[19–21]. Antidepressants are effective essentially on
depressive aspects [16]. Benzodiazepines, which are
used if other agents have failed [22], may lead to
increased confusion and falls, and rarely to a para-
doxical increase of agitation in the elderly [23].
BPSD treatment is therefore unsatisfactory, and
the anticholinergic propriety of many drugs used
for treating various disorders, occurring often in the
elderly, represents a further limitation [24]. Cholin-
ergic dysfunctions are not only associated with
cognitive impairment, but probably also with BPSD
[25, 26]. This hypothesis is further supported by the
reported benefits of treatment with cholinesterase
inhibitors on BPSD [25, 26]. Rivastigmine, in fact,
has been shown to reduce apathy, anxiety, depression,
and delusions [27] and donepezil and galantamine to
decreased delusion, hallucinations, agitation [28, 29],
depression, apathy, and anxiety [27, 28].
From a theoretical point of view, symptoms caused
directly or indirectly by impaired brain cholinergic
neurotransmission could benefit from an enhanced
cholinergic neurotransmission and by increasing
acetylcholine bioavailability. In this study, we have
explored this hypothesis by evaluating BPSD in
two matched groups of AD subjects, treated for 24
months with a cholinesterase inhibitor alone (group
A) or with the association of the same cholinesterase
inhibitor to the cholinergic precursor choline
alphoscerate (alpha-glyceryl-phosphorylcholine)
(group B). Preclinical studies have shown that
choline alphoscerate alone or in association with
an acetylcholinesterase-inhibitor (AChE-I) has
an enhancing effect on cholinergic transmission
[30–33]. Starting from these observations, we
have investigated in a clinical trial the effect of
association of choline alphoscerate with the AChE-I
donepezil on BPSD in AD. The activity of the
association was compared to that of donepezil alone.
METHODS
Patients and study type
Patients described here were all included in
the double blind randomized trial ASCOMALVA
(Association between the Cholinesterase Inhibitor
Donepezil and the Cholinergic Precursor Choline
Alphoscerate in Alzheimer’s Disease). This trial was
aimed to compare the cognitive effects of the treat-
ment with donepezil plus the cholinergic precursor
choline alphoscerate versus donepezil only in sub-
jects with mild/moderate AD.
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Table 1
Patient dropout causes in ASCOMALVA trial
Dropout causes in ASCOMALVA trial
Causes of dropouts No. Donepezil + placebo No. Donepezil + choline
alphoscerate
Total 12 17
Death 0 1
Lack of efficacy 0 2 Disease worsening
Non compliance 3 Transferred to geriatric 3 Transferred to geriatric
homecare support homecare support
Lack tolerability 3 1 Hallucinations, 3 1 Hallucinations,
asthenia insomnia
1 Diarrhea, vomiting
2 Diarrhea, vomiting 1 Cutaneous rash
Other reasons 6 5 Difficulty to 8 3 Difficulty to
displace displace
2 Home change
1 Unknown 3 Unknown
For clarity, the main characteristics of the ASCO-
MALVA study are detailed below. Further details are
reported in previous studies of our group [34–36].
Patients, diagnosed according to NINCDS-ADRDA
criteria, were all in a mild/moderate-stage, showed
brain ischemic lesions (in CT or MRI), and had at
least two vascular risk factors (such as hypertension,
diabetes, obesity, ischemic heart disease, hyper-
cholesterolemia, hyperhomocysteinemia, smoking,
previous cerebrovascular events, or family history of
cardio-cerebrovascular diseases). This to confirm the
diagnosis of cerebrovascular impairment [37, 38].
Two matched groups were analyzed: one (group
A) treated with donepezil 10 mg/day plus choline
alphoscerate 1,200 mg/day (associative therapy), the
other (group B) with donepezil 10 mg/day + placebo
(mono therapy). 175 subjects out of the originally
planned 210 were recruited and 29 dropped out (12
in the donepezil only group, and 17 in the associa-
tive therapy group) for different causes, indicated in
Table 1. The interim results reported in this paper
involved 113 subjects treated for 24 months. It was
found, at 24 months of treatment, that group A sub-
jects performed significantly better than group B on
cognitive [Mini Mental State Examination (MMSE),
Alzheimer’s Disease Assessment Scale Cognitive
subscale (ADAS-Cog)], functional [Basic Activities
of Daily Living (BADL), Instrumental Activities of
Daily Living (IADL)], and behavioral scales [Neu-
ropsychiatric Inventory (NPI)] [34–36].
This paper refers to the same patient population
already described [34–36] and was aimed to pro-
vide a more accurate evaluation of the behavioral
effect observed on the different sub-items of the NPI.
This to assess if any specific symptom or symptoms
Table 2
Demographic characteristics of patients participating
to the ASCOMALVA trial
113 subject (43 males)
Monotherapy Associative
Age (y) 78 ± 5 76 ± 8
Sex 20 males 23 males
36 females 34 females
Education (y) 7 ± 3 8 ± 5
Mean MMSE at baseline 20.3 ± 2.9 19.9 ± 3.1
MMSE 24–21 42.9% 37.5%
MMSE 20–18 39.3% 25%
MMSE <17 17.9% 37.5%
cluster was influenced by the therapy. BPSD pres-
ence and severity was investigated at the baseline,
after 12 months and after 24 months by the NPI rel-
atively to each of its sub-items. The severity of the
caregiver distress by the NPI-Distress of caregiver
was assessed as well. The sample consists of 113 sub-
jects, whose demographic characteristics are reported
in Table 2. All subjects were community dwelling,
were enrolled in the study at least 6 months after
the diagnosis, and none had received any specific
previous treatment. The other psychoactive drugs
assumed by each patient at the baseline and the fol-
low up were registered together with their eventual
dosage changes. These drugs were classified into
three categories: antipsychotics, antidepressants, and
anxiolytics.
Procedures
BPSD presence and severity were measured
by the subscales of the Neuropsychiatric Inven-
tory NPI [39]. The NPI assesses the frequency
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Fig. 1. Correlation between the age of the whole sample and the severity of behavioral symptoms (NPI-F) at baseline and after 24 months
of treatment assessed by the test of Pearson. NPI, neuropsychiatric inventory.
and the severity of the symptoms and the
caregiver distress in 12 behavioral domains (delu-
sions, hallucinations, depression/dysphoria, anxi-
ety, agitation/aggression, elation/euphoria, disinhibi-
tion, irritability/lability, apathy/indifference, aberrant
motor activity, sleep/night time behavior, and
appetite/eating) [39]. NPI is given as an interview
questionnaire, and neuropsychiatric manifestations
within each domain are rated by the caregiver
in terms of both frequency (1–4) and severity
(1–3), yielding a composite symptom domain score
(frequency×severity: NPI-F). The caregiver distress
(NPI-D) is rated for each positive neuropsychiatric
symptom domain by scores from 0 (no distress) to
5 (extreme distress). The total composite score is
obtained by summing up the single item score, which
may range from 0 to 144, with higher scores indicat-
ing more behavioral problems. In addition, a score
for the caregiver stress is assigned for each type of
the abnormal behavior found. The total distress score
may range from 0 to 60, with higher scores indicating
more severe distress suffered by the caregiver.
Statistics
The correlation between the age and gender of the
whole sample and the severity of behavioral symp-
toms (NPI-F) was assessed by the test of Pearson.
NPI-F, NPI-D, and each sub-item was evaluated
at baseline and each follow up. Analysis of variance
(ANOVA) and multivariate ANOVA were used. A
two tailed Student “t” test was then used to evaluate
the significance of differences between each group.
To assess if the use of antidepressants, anxiolytics,
and antipsychotics modified significantly the severity
of symptoms, chi square test (χ2) was employed.
RESULTS
The 113 patients investigated (43 M), were treated
with donepezil (10 mg/day) + choline alphoscerate
(1200 mg/day) (n = 57, group A) or with donepezil
+ placebo (10 mg/day) (n = 56, group B). Groups
were matched for age (76 ± 8 y in group A, 78 ± 5 y
in group B) and sex (23 males in group A, 20 in
group B) and MMSE at baseline. The distribution
of mild/moderate cases within the two groups are
detailed in Table 2. Vascular risk factors were found
in both groups. Arterial hypertension was the most
common (87.4%), followed by a family history of
cardio-cerebrovascular diseases (74.8%), hyperc-
holesterolemia (61.4%), diabetes (29.9%), smoking
(28.3%), obesity (26.8%), hypertriglyceridemia
(24.4%), previous ischemic stroke (20.5%), transient
ischemic attack (17.3%), ischemic heart disease
(14.2%), and hyperhomocysteinemia (0.8%). No
differences between groups in the total number of
vascular factors were noticeable (Table 3). Composite
cardiovascular [40] and cerebrovascular [41] burden
were also calculated, and showed no significant
differences within the two groups (data not shown).
The correlation between the age of the whole
sample and the severity of behavioral symptoms
(NPI-F) showed no differences at the baseline nor
after 24 months (Fig. 1). At baseline, the severity of
behavioral symptoms (NPI-F) was greater in females
(NPI-F = 22) than in males (NPI-F = 16). After 24
months, the NPI-F female averaged 24.9 and the
NPI-F male 24.2 (Fig. 2), indicating that baseline
differences did no longer occur at the end of the
observation time. Among the different neuropsychi-
atric symptoms, agitation (13%), depression (21%),
anxiety (15%), apathy (18%), and irritability (12%)
were mostly found (Fig. 3).
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Table 3
Vascular risk factors of the subjects participating to the ASCOMALVA trial
A B C D E F G H I J K
Total no 12.6 70.1 38.6 75.6 73.2 79.5 85.8 82.7 71.7 99.2 25.2
yes 87.4 29.9 61.4 24.4 26.8 20.5 14.2 17.3 28.3 0.8 74.8
Monotherapy no 8.6 69.0 44.8 72.4 72.4 81.0 82.8 82.8 72.4 98.3 32.8
yes 91.4 31.0 55.2 27.6 27.6 19.0 17.2 17.2 27.6 1.7 67.2
Association therapy no 15.9 71.0 33.3 78.3 73.9 78.3 88.4 82.6 71.0 100.0 18.8
yes 84.1 29.0 66.7 21.7 26.1 21.7 11.6 17.4 29.0 0.0 81.2
A) arterial hypertension; B) diabetes; C) hypercholesterolemia; D) hypertriglyceridemia; E) obesity; F) ischemic stroke; G) ischemic heart
disease; H) transient ischemic attack; I) smoking; J) hyperhomocysteinemia; K) family history; No, absent; Yes, present.
Fig. 2. Correlation between sex and severity of the behavioral
symptoms (NPI-F) in the whole sample.
At the baseline, the global NPI severity and fre-
quency (NPI-F) and the caregiver distress (NPI-D)
were not different between groups (Table 4), whereas
after two years of treatment the NPI-F and NPI-D
in group A subjects were significantly lower than in
group B (Table 4). Variations from baseline of NPI-F
and NPI-D are shown in Fig. 4a and 4b, respectively.
Assessment of each single NPI item showed that, after
treatment, group A subjects had less depression and
apathy than group B subjects (Table 4), whereas anx-
iety was reduced significantly in group A and not in
group B subjects (Table 5).
Table 6 summarizes data on patients taking psy-
choactive drugs (antidepressants, anxiolytics, and
antipsychotics), including the mean doses of dif-
ferent compounds used. After 24 months, the
global assumption of antidepressants and anxiolytics
decreased, whereas administration of antipsychotics
increased (Fig. 5). On comparing the two treatment
Fig. 3. Presence of the different BPSD (NPI-F) in the patients participating to the trial.
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12 months 24 months 12 months 24 months
donepezil donepezil + choline alphosceratedonepezil donepezil + choline alphoscerate
Fig. 4. Variations from baseline of severity and frequency of symptoms of NPI (NPI-F) (A) and of the caregiver distress measures of NPI
(NPI-D) (B) ∗Significantly different p < 0.05 by t-Student test versus baseline. #Significantly different p < 0.05 by ANOVA test versus
donepezil.
Table 4
Severity and frequency (NPI-F) and caregiver distress (NPI-D) assessed by NPI at the baseline, at 12 and 24 months in the two patient groups
of the trial
113 SUBJECTS (43 males)
Baseline 12 months 24 months Difference between
baseline and 24th month
MT AT MT AT MT AT MT AT
NPI (FxS) 19.7 ± 13.8 22.6 ± 15.8 18.6 ± 15.4 20.1 ± 17.4 29.0 ± 19.0* 22.1 ± 16.1** 9.2 ± 23.3 –0.5 ± 14.1∗∗
NPI (stress) 9.6 ± 6.7 11.5 ± 8.3 12.2 ± 8.7 10.8 ± 10.2 18.7 ± 15.6* 11.9 ± 9.6** 9.1 ± 16.4 0.4 ± 8.7∗∗
Values are expressed as the means ± S.D. NPI, FxS (Neuropsychiatric Inventory severity multiplied by gravity); NPI stress, Neuropsychiatric
Inventory caregiver distress; MT, monotherapy, donepezil + placebo; AT, association therapy: donepezil + choline alphoscerate. *Significantly
different p < 0.05 by t-Student test versus baseline, **Significantly different p < 0.05 by ANOVA test versus monotherapy.
Table 5
Anxiety, depression, and apathy subscale of NPI at the baseline, 12 and 24 months in the two groups of patients of the trial
113 SUBJECTS (43 males)
Baseline 12 months 24 months Difference between baseline
and 24th month
MT AT MT AT MT AT MT AT
Anxiety 3.1 ± 4.1 3.3 ± 3.9 2.0 ± 2.4 2.1 ± 3.3 3.0 ± 3.8 1.5 ± 2.4* –0.1 ± 5.6 –1.8 ± 3.9**
Depression 4.2 ± 4.2 4.7 ± 4.4 3.7 ± 3.4 3.3 ± 3.1 6.3 ± 4.4* 4.6 ± 4.2 2.1 ± 6.4 –0.1 ± 5.0**
Apathy 3.2 ± 3.9 4.2 ± 4.5 4.9 ± 4.7 3.3 ± 4.3 6.8 ± 4.8* 4.8 ± 4.9 3.6 ± 4.8 0.6 ± 6.1**
Values are expressed as the means ± S.D., MT, monotherapy, donepezil + placebo; AT, association therapy: donepezil + choline alphoscerate,
*Significantly different p < 0.05 by t-Student test versus baseline; **Significantly different p<0.05 by ANOVA test versus monotherapy.
groups investigated, after 24 months, the use of
antipsychotic drugs increased and the use of anxi-
olytics decreased in both groups. Antidepressants use
remained the same as in the group A, but decreased
in the group B (Fig. 6).
Consumption of antidepressants and anxiolytics
was compared versus the improvement in apathy and
anxiety by the chi square test (χ2) (Fig. 7). Among
subjects in which depression was improved, 56%
were in group A and only the 12% of those used
antidepressants for 24 months. In subjects in which
apathy improved, one half was in group A, and none
of them were treated with antidepressants. In subjects
with anxiety improved, 62.1% belonged to the group
Fig. 5. Drug consumption from global sample at baseline and after
24 months of treatment.
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Fig. 6. Drug consumption in monotherapy group versus association therapy group.
Table 6
Percentage of subjects receiving the different psychoactive drugs and their mean dose at baseline and after 24 months of treatment.
Baseline 24 months
Drug Dose % of patients Drug Dose % of patients
Antipsychotics
Quetiapine 25 mg 33.3 Seroquel 25 mg 18.8
50 mg 33.3 50 mg 25
100 mg 16.7 100 mg 25
Risperidone 2 mg 16.7 150 mg 6.3
400 mg 6.3
Risperdal 2 mg 6.3
Other drugs 12.5
Antidepressants
Duloxetine 30 mg 10.5 Cymbalta 30 mg 7.1
60 mg 15.8 60 mg 21.4
Citalopram 10 mg 21.1 Cipralex 10 mg 21.4
Setraline 50 mg 15.8 Zoloft 50 mg 7.1
Other drugs 36.8 Other drugs 42.9
Anxiolytics
Lorazepam 1 mg 18.2 Lorazepam 1 mg 28.6
Prazepam 10 mg 9.1 Prazene 10 mg 0
20 mg 18.2 20 mg 14.3
Other drugs 54.5 Other drugs 57.1
A, and only 6.9% used anxiolytics at the 24th month
of observation (Fig. 7).
DISCUSSION
The BPSD, a group of very common symptoms
in AD [39], can be assessed by standardized instru-
ments such as the NPI [39, 42]. Leading to high
disability and poor quality of life [43], BPSD are a
further cause of distress in caregivers [44, 45] and
the main reason of the early institutionalization of
patients [46]. The occurrence of BPSD raises sev-
eral ethical and legal medical problems such as to
establish the level of remaining autonomy, such as
if patients are still able to have enough understand-
ing/knowledge about their disease to decide on their
treatment and make plans for the future [47, 48].
Another relevant ethical problem is the opportunity of
treating BPSD with antipsychotic drugs. These com-
pounds are at high risk of adverse events, even at
modest doses, and may interfere with the progression
of cognitive impairment. Moreover, they could inter-
act with several drugs including anti-arrhythmics and
AChE-I [49].
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Fig. 7. Percentage of patients consuming drugs who had an improvement in the respective NPI parameter. No significant increase in frequency
of patients who showed improvement in NPI subscales was seen among those patients that at the same time consumed specific drugs for
their behavioral disorder.
Causes and pathophysiology of BPSD are incom-
pletely understood. These problems have been
associated with the imbalance of several neu-
rotransmitters and particularly to a cholinergic
dysfunction in several brain regions including the
limbic system (hippocampus, amygdala, anterior
thalamus, hypothalamus, basal forebrain, mam-
millary bodies, and septal area) and the cingu-
lated, orbitofrontal, and parahippocampal cortices
[42, 50, 51]. The high levels of acetylcholinesterase
(AChE), found in the hippocampus, amygdalae, and
thalamus, have suggested that the inhibition of this
enzyme might be useful for treating BPSD [52].
This hypothesis was supported from studies show-
ing a beneficial effect of ChEI on BPSD reduction
[27, 53, 54, 55, 56] and specific activity of donepezil
in particular on some symptoms, such as apathy, anx-
iety, agitation, and depression [28, 57].
In this work, we have evaluated the BPSD burden
in 113 mild/moderate AD subjects, all included in
the double-blind trial ASCOMALVA. We have found
that subjects treated with the association of donepezil
and choline alphoscerate had a lower NPI score.
The caregiver stress of these subjects was, accord-
ingly, lower. A significant difference was found in
the cluster “mood disorders” of the BPSD, which
refers to depression, anxiety, and apathy/indifference.
This cluster of symptoms has been attributed to the
disconnection between the neocortex and the basal
nuclei, which would deprive the cortex of its major
source of acetylcholine. Consequently, the ability to
properly process the emotional significance of stim-
uli would be impaired [58], leading to apathy [19].
Theoretically, apathy would improve if higher lev-
els of acetylcholine would be available, an aspect
we have already described [36]. Beneficial effects
of donepezil on depression and anxiety have already
been reported [28, 57, 59]. This study has shown that
the association of donepezil to choline alphoscerate
has greater efficacy on symptoms of mood disorders
such as apathy, depression, and anxiety, improving
them more than when donepezil was administered
alone.
It might be hypothesized that the occurrence of
vascular lesions and risk factors in our sample may
represent a limit to the generalization of the results to
the whole AD population. However, it should be con-
sidered that the presence of cerebrovascular injury
occurs in the majority of AD subjects [37]. Hence,
AD degeneration plus vascular damages probably is
the prevalent phenotype of these subjects [37]. It may
be worthy, furthermore, to underline that the vas-
cular burden did not show differences between the
groups.
AD patients’ treatment obviously included other
drugs, whose potential interference has been consid-
ered. We have therefore evaluated if any significant
difference in the assumption of psychoactive drugs
(antipsychotics, antidepressant, and anxiolytics)
occurred in the two treatment groups. This anal-
ysis has shown that the percentage of patients
assuming antipsychotics was higher in both groups
A. Carotenuto et al. / Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer’s Disease 813
after 24 months, compared to the baseline. These
findings indicate the progression of AD. However,
most patients with improved mood symptoms after 24
months did not take antidepressants and anxiolytics,
suggesting that this improvement can be related to the
cholinergic effect. The antidepressants and anxiolyt-
ics administered to our patients probably have a weak,
if any, cholinergic effect as only trazodone has some
anti-cholinergic activity [60], whereas duloxetine, the
most used, has no effect at all. Among the antipsy-
chotics neither quetiapine nor risperidone interfere
with the cholinergic neurotransmission [61].
This study has strengths and weaknesses: the
longtime of observation and treatment (24 months)
represent strengths, while the size of the sample and
the nature of the post hoc type of data are weaknesses.
We are also aware that the NPI score, being dependent
from the caregiver input, is influenced by the care-
giver mood, his burden, and belief system [62, 63].
However, this test is, up to now, one of the most
widely used in clinical trials on the BPSD. Finally,
we are aware that the prescription of psychiatric
drugs usually cuts across their specific categories, i.e.,
antipsychotics are frequently used as “tranquilliz-
ers” and antidepressants to treat anxiety [64]. Future
developments of this research should include a longer
observation period and the stratification of the sam-
ple according to the severity of the neuropsychiatric
symptoms.
In conclusion, globally our findings suggest that
the association of donepezil (10 mg/day) to choline
alphoscerate (1200 mg/day) may be a beneficial
option in reducing BPSD of mild/moderate AD
patients and should be considered especially when
BPSD are unresponsive to donepezil only, or when
the caregivers are unsatisfied with donepezil alone.
Beneficial effects should also be evaluated in terms
of the reduction of other potentially dangerous drugs
given for the BPSD. A larger clinical trial is obvi-
ously warranted to further determine the efficacy and
the advantages of the treatment.
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